| WHAT IS K NOWN AND OBJEC TIVE
Selenium (Se) has been supported to be an essential trace element for human health, 1 especially for the thyroid gland, 2 which is the organ with the highest Se concentration per gram of tissue, implying its fundamental role in thyroid cell physiology. 3 Se is a basic structural component of at least 25 known proteins, the so-called selenoproteins, including enzymes functionally active in the thyroid gland. Glutathione peroxidase (GPx), thioredoxin reductase (TxR) and iodothyronine deiodinases are among the best-described selenoproteins. 1 GPx and TxR exert antioxidative, immunoregulatory and anti-inflammatory action. GPx and TxR can reduce hydrogen peroxide (H 2 O 2 ), required for thyroid hormone synthesis, as well as lipid and phospholipid hydroperoxides. As a result, they contribute to redox balance by eliminating the accumulation of free radicals and reactive oxygen species (ROS). Through their antioxidative effect, they might impair T cell-mediated and B cell-mediated immunity. 4, 5 Furthermore, lower hydroperoxide thyroid levels lead to diminished production of inflammatory prostaglandins and leukotrienes through cyclooxygenase and lipoxygenase pathways. 6 On the other hand, iodothyronine deiodinases regulate thyroid hormone concentrations, as they catalyze the conversion of prohormone thyroxine (T4) to active triiodothyronine (T3) or inactive reversible T3. 7 In case of Se deficiency, oxidative damage is promoted and autoimmune processes are induced via diminished GPx and TxR function, whereas thyroid hormone synthesis is impaired due to reduced deiodinases activity. 8, 9 Autoimmune thyroiditis (AT) is the most common cause of acquired hypothyroidism among children and adolescents in iodinesufficient areas. 10 It is characterized by inflammatory lymphocytic infiltration of the thyroid gland through both T cell-mediated and B cell-mediated immune responses. 11 The diagnosis is based on the presence of antibodies against thyroid peroxidase (anti-TPO) and/or thyroglobulin (anti-Tg) and hypoechogeneity in thyroid gland ultrasonography, implying lymphocytic infiltration of thyroid gland.
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As Se deficiency may be involved in initiation or progression of thyroid autoimmunity, 8, 9 it has been hypothesized to be implicated in the pathogenesis of AT. 12, 13 Several studies aimed to investigate the potential therapeutic benefit of Se supplementation either as l-selenomethionine or as sodium selenite in patients with AT. They included adults, but differences were recorded regarding baseline Se level, form of supplementation and duration of intervention, preventing from making safe conclusions. [14] [15] [16] [17] [18] [19] [20] [21] Se supplementation has been documented to have beneficial effects in adult patients with AT, especially in those with higher antithyroid antibody levels and increased inflammatory disease activity. [15] [16] [17] In a meta-analysis, these effects were detected especially on anti-TPO titre. 22 However, data are unclear and the real efficacy of Se supplementation in AT needs further investigation. 23 Data obtained from paediatric populations are scarce and inconclusive as well. 24, 25 The aim of the present study was to investigate whether daily supplementation with organic Se at a high dose (200 μg l-selenomethionine) has any effect on antithyroid antibody titres in children and adolescents with AT.
| ME THODS

| Participants
Patients with a diagnosis of AT, made before the age of 18 years, who were under follow-up at outpatient clinic of our department, were finally included if they fulfilled the following criteria: seropositivity for anti-TPO and/or anti-Tg ≥60 IU/mL, accompanied by euthyroidism or hypothyroidism treated with levothyroxine (l-T4), and presence of goitre on thyroid gland ultrasonography.
They did not receive any other treatment except l-T4, and they were otherwise healthy, without any diagnosis of other autoimmune disease or thyroid adenoma. They were recruited from August 2014 to October 2016. Initially, 89 patients were included, but, subsequently, 18 patients were excluded from analysis due to the following reasons: five patients because they preferred to receive the relevant commercially available product, 11 patients because seropositivity for antithyroid antibodies was not confirmed at inclusion, whereas in two patients, antithyroid antibody concentration was not accurately measured (the upper limit was not determined). Informed written consent was obtained from all parents or guardians of the participants.
| Study design protocol
A single-centre, randomized, double-blind, placebo-controlled clini- gov database (ID NCT02644707). In detail, participants were randomized into two groups, using a random number anti-TPO and anti-Tg levels. A thyroid gland ultrasonography of all participants was also performed at inclusion in the study. Clinical and laboratory follow-up of patients was done at regular intervals of 3 and 6 months, whereas thyroid gland ultrasonography was repeated only at the last follow-up visit (after 6 months). During the study period, in order to increase the compliance of participants to treatment and to assess whether any adverse events occurred, one phone contact was scheduled once monthly, whereas tablet blisters were requested to be returned at every next follow-up visit as well.
The primary outcome of the study was to determine and compare any changes in anti-TPO and anti-Tg titres between children and adolescents with AT receiving l-selenomethionine and those receiving placebo. Secondary outcomes were to investigate whether there is any beneficial effect of Se supplementation on l-T4 substitution dose (μg/kg body weight/d) in the sub-group of hypothyroid patients (as they were defined at inclusion in the study), on the need for initiation of l-T4 substitution therapy in the sub-group of euthyroid patients as well as on the thyroid gland volume as evaluated by ultrasonography after a period of 6 months.
| Assays
Serum fT4 
| Ultrasonography
| Statistical analysis
Statistical analysis was performed using the statistical package for social sciences software version 16.0 (SPSS Inc, Chicago, IL, USA). Data are presented as mean values ± standard error (SE) for all variables unless otherwise stated. Categorical variables (percentages %) were compared using the chi-squared test. All continuous variables were tested for normal distribution by the Shapiro-Wilk test. Differences in continuous variables between the two study groups were tested with the t test or the non-parametric Mann-Whitney test. Differences in continuous variables between the two study groups at the entry and at the completion of the study were tested with the paired t test or the non-parametric Wilcoxon rank test, as appropriate. All tests were two-sided, and the level for statistical significance was set at P < 0.05.
| Sample size
For the calculation of sample size, we used the formula [N = 2 * σ
where N was the number of patients required in each study group, Z α was a constant equal to 1.960 at the level of statistical significance 5%, Z 1−β corresponded to a value of 0.842 for achieving a statistical power of 80%, δ was the expected detectable difference in the decrease in antithyroid antibody titres between intervention and control group (that was the main end point of the study, estimated to be 100 IU/mL), whereas σ was its estimated standard deviation (SD) in the paediatric population (given the value of 150 IU/mL). Based on these data, we calculated that the number of patients needed in each arm was 35.
| RE SULTS AND D ISCUSS I ON
This study included 71 children and adolescents (14 boys/57 girls).
The mean age of the patients was 11.3 ± 0.3 years (range 4.5-17.8).
The intervention group included 38 patients, whereas the control group 33 patients. An increased (age-based) thyroid gland size was found in 15.5% of patients. Hypothyroidism (treated with l- The characteristics of the individuals in each group at the beginning and the end of the study are shown in Table 1 . The two study groups did not differ statistically significantly in age, gender, body mass index (BMI) or the presence of goitre, but they differed in the status of thyroid function (more hypothyroid patients in the intervention group). In regard to the titre of antithyroid antibodies, at the beginning of the study, no differences between the two study groups were detected (Table 1) . On the other hand, when comparing the variation in antithyroid antibody levels between the two study groups at the beginning and at the end of the study, a significantly greater reduction in anti-Tg levels was recorded in the intervention group vs the placebo group (Table 1) . In contrast, although anti-TPO levels were decreased in the intervention group and increased in the placebo group, this between-group difference was not statistically significant. In addition, there was no statistically significant difference in the variation in thyroid gland volume between the two study groups (Table 1) . Interestingly, no significant differences between the sub-groups of hypothyroid/euthyroid patients were detected in terms of Se supplementation effect on dose and need of thyroxine substitution therapy, respectively (Table 1 ). All patients completed the study without reporting any side effects, with the exception of one patient, who temporarily complained of rash; however, after receiving the history in detail, anti-Tg titre may be reduced in 12 months compared to those receiving placebo. 28 A recently published meta-analysis of sixteen clinical trials suggested that Se supplementation reduced anti-TPO levels after 3, 6 and 12 months in AT patients receiving l-T4 and after 3 months in untreated patients. In regard to anti-Tg levels, it was also observed a reduction after 3 months but not after 6 or 12 months of supplemental Se administration in untreated patients. 29 The most recently published systematic review and meta-analysis in 2017, based on eleven and five studies, respectively, argues that Se supplementation for the treatment of AT is not proposed because of conflicting reports. 23 Similarly, a systematic review of the Cochrane Collaboration in 2013, which included four studies, indicated a paucity of objective evidence to support Se supplementation as a complementary therapy for patients with AT. 30 However, the correction of Se deficiency is considered to be entirely justified in order to prevent its negative effects on health. 29 It is obvious that there is a need for evidence-based, long-term, randomized, placebo-controlled studies in order to make safe conclusions.
On the other hand, there are insufficient data on Se supplementation in children and adolescents with AT. The first study by Bonfig with AT has not been further investigated. Furthermore, the two published studies are characterized by methodological differences, mainly in the form and dose of Se supplementation. In the first trial, sodium selenite was administered at low and high dose, 24 whereas in the second one, l-selenomethionine at low dose. 25 In contrast, in the present study, we investigated for the first time the effect of l-selenomethionine at the high dose of 200 μg daily in children and adolescents with AT. At the end of the intervention, anti-Tg but not TA B L E 1 Differences in various parameters between the two study groups at the beginning and at the end of the study anti-TPO levels were found to be statistically more decreased in the intervention group as compared to the placebo group. At the same time, nonsignificant regression of thyroid gland enlargement was observed. These results as those of other studies concerning paediatric population 24,25 offer insight into the natural course of AT at the early stages, thus implying that once thyroid autoimmunity is triggered, it is not reversed.
The lack of statistically significant effect of Se supplementation on anti-TPO titres in children and adolescents with AT is consistent with the two previously published studies involving children. 24, 25 On the other hand, initial studies 14, [16] [17] [18] 31 in adults supported the beneficial effect of Se on anti-TPO levels. Since then, as it becomes obvious from the meta-analyses, 28, 29 there is a wide varia- in anti-Tg levels in 24 patients with subclinical hypothyroidism due to AT. It is noteworthy that a negative correlation, however, not statistically significant was observed between Se levels and antiTg titres in 100 euthyroid AT patients. 35 Significant reduction in anti-Tg levels was observed after administration of 160 μg l-selenomethionine for 12 months in euthyroid women with AT. 34 In the present study, it is noteworthy that when we took into account the increased proportion of hypothyroid patients under l-T4 in the intervention group compared to the placebo group, statistical significance was lost. Therefore, the result should be interpreted with scepticism in accordance with other authors in case of confirmation of the effect of Se on anti-Tg titres. It is characteristic that Turker et al 16 did not attributed the reduction in anti-Tg concentrations in the therapeutic effect of Se due to their low specificity in AT. As a result, some studies did not include the effect of Se on anti-Tg levels in their purposes. 14, 18, 31, 40 No increase in l-T4 substitution dose under the potential effect of Se supplementation is of clinical interest. A mild increase in l-T4
dose after 6-months of Se supplementation was observed in both the intervention and the placebo groups in our study; however, the comparison did not reach the level of statistical significance, thus indicating that any detected difference is attributed to the natural history of the disease or explained by increase in body weight and body surface. The absence of statistically significant variation in l-T4 substitution dose is in accordance with the results of other studies. [15] [16] [17] 39 Similarly, in euthyroid patients, no statistically significant difference in those who started and those who did not start l-T4 substitution therapy within the study period was recorded.
Finally, the nonsignificant variation in thyroid gland volume in the present study should be approached with caution, taking into account the expected normal increase in thyroid gland volume during the intervention period. Onal et al 25 showed significant thyroid gland regression, with thyroid gland volume returning to normal after early intervention with Se.
Among the advantages of the present study is the design of a randomized, double-blind, placebo-controlled clinical study, which is considered the hierarchical peak of evidence-based medicine and the fact that administration of organic Se at the high daily dose of 200 μg is investigated for the first time in a paediatric population with AT. Whether this dose remains within the acceptable amount of safe total daily Se intake or not, it should be taken into account that the safe total daily Se intake from all nutritional sources for a 70 kg adult has been set at 350 μg/d, corresponding to 5 μg Se/kg body weight/d, 43 a cut-off point which is close to the Se dose administered in our patients. In contrast, a potential restriction of the present study is the fact that serum Se levels of the participants were not measured prior to the study; hence, the value of substitution therapy with Se supplements in patients with AT cannot be safely predicted. However, the fact, that our patients came from a European region where Se content is relatively low, is in favour of a possible beneficial effect of Se supplementation on thyroid autoimmunity. In a study conducted in Greece, 87.6% of healthy women and 88.5% of healthy men had serum selenium levels below 125 μg/L considered to be the required cut-off for optimal GPx activity. 44 Furthermore, excess Se intake is excreted in urine and faeces and Se supplementation with doses of 300 μg is well absorbed and tolerated. 45 On the other hand, even if we had carried out these measurements, this limitation would have been still present; besides, intrathyroid Se concentration has been previously suggested to be more important than serum Se levels in influencing antithyroid antibody titres. 38 It is of interest that in the study by Onal et al 25 including children, the paradoxical decline in serum Se levels after 3-month Se supplementation was explained by the potential variability in intrathyroid Se concentrations, not correlating with serum Se levels.
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